

Glenmark - Recall of arformoterol inhalation solution

On April 25, 2022, <u>Glenmark announced</u> a consumer-level recall of several lots of <u>arformoterol</u> inhalation solution due to a lack of assurance of product sterility discovered after a review of the manufacturing facility's microbiology laboratory controls and processes.

Product Description	NDC#	Lot# (Expiration Date)
Arformoterol 15 mcg/ 2 mL inhalation solution	68462-833-35	30210041 (3/31/2023); 30210045 (3/31/2023); 30210046 (4/30/2023); 30210050 (4/30/2023); 30210051 (4/30/2023); 30210058 (4/30/2023)
	68462-833-65	30210042 (3/31/2023); 30210047 (4/30/2023); 30210048 (4/30/2023); 30210052 (4/30/2023); 30210053 (4/30/2023); 30210054 (4/30/2023); 30210059 (4/30/2023); 30210060 (4/30/2023); 30210061 (4/30/2023); 30210062 (4/30/2023); 30210064 (5/31/2023);

- Arformoterol inhalation solution is indicated for the long-term, twice daily maintenance treatment
 of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic
 bronchitis and emphysema.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- Patients should contact their physician or health care provider if they have experienced any
 problems that may be related to taking or using the recalled arformoterol.
- Contact Qualanex by phone at 1-888-504-2012 or by email at recall@qualanex.com for return information and for more information about the recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.